CNS Pharmacology: Antipsychotics

Introduction / Overview

Antipsychotic agents constitute a cornerstone of treatment for a spectrum of psychiatric disorders, primarily schizophrenia, bipolar disorder, and various psychotic manifestations. Their clinical significance is underscored by the prevalence of psychotic disorders globally and the substantial morbidity associated with inadequate symptom control. Understanding the pharmacologic underpinnings of antipsychotics enables clinicians to tailor therapies, anticipate adverse events, and navigate complex drug interactions.

Learning objectives for this chapter include:

• Identify the major pharmacologic classes of antipsychotics and their chemical relationships.
• Describe the principal receptor targets and downstream signaling pathways affected by antipsychotic drugs.
• Interpret key pharmacokinetic parameters that influence dosing strategies and therapeutic monitoring.
• Recognize approved therapeutic indications, off‑label applications, and contraindications.
• Summarize common and serious adverse reactions, including black‑box warnings, and outline strategies to mitigate risk.

Classification

Major Drug Classes

• First‑generation (typical) antipsychotics – primarily dopamine D₂ receptor antagonists, including chlorpromazine, haloperidol, and fluphenazine.
• Second‑generation (atypical) antipsychotics – broader receptor profile with antipsychotic activity and reduced extrapyramidal risk, such as clozapine, risperidone, olanzapine, quetiapine, and ziprasidone.

Chemical Families

Antipsychotics can be grouped according to core chemical structures:

• Phenothiazines – core tricyclic heteroaromatic scaffold; e.g., chlorpromazine.
• Butyrophenones – linear structure with a butyrophenone core; e.g., haloperidol.
• Thienobenzodiazepines – thienodiazepine core; e.g., clozapine.
• Isochroman derivatives – chiral molecules with an isochroman core; e.g., risperidone.
• Indole alkaloids – indole nucleus; e.g., ziprasidone.

Mechanism of Action

Pharmacodynamics Overview

Antipsychotics exert their therapeutic effects primarily through modulation of dopaminergic neurotransmission. Classic antipsychotics block dopamine D₂ receptors in mesolimbic pathways, attenuating positive psychotic symptoms. Atypical agents possess a more complex receptor affinity profile, including serotonin 5‑HT₂A antagonism, which is proposed to confer efficacy against negative symptoms and reduce extrapyramidal toxicity.

Dopamine Receptor Interaction

Binding affinity (K_i) values for D₂ receptors vary across agents. High‑affinity typical agents (K_i 80 %), whereas atypicals often display lower D₂ affinity (K_i 5–10 nM) with additional serotonergic activity. The ratio of 5‑HT₂A to D₂ affinity is a useful metric for predicting side‑effect profiles.

Serotonin and Other Receptor Targets

Serotonin 5‑HT₂A antagonism is common among atypicals and is implicated in alleviating negative symptoms and mitigating extrapyramidal manifestations. Some atypicals also inhibit 5‑HT₂C, H1 histamine, muscarinic M1, and adrenergic α1 receptors, contributing to sedation, weight gain, and orthostatic hypotension. Off‑target receptor interactions can also explain idiosyncratic adverse events such as agranulocytosis (clozapine) or QT prolongation (ziprasidone).

Molecular and Cellular Mechanisms

Beyond direct receptor blockade, antipsychotics influence downstream signaling cascades. Dopamine D₂ antagonism diminishes G_i/o protein activity, reducing cyclic AMP production and altering neuronal firing rates. Serotonergic antagonism at 5‑HT₂A receptors modulates calcium signaling and cortical neurotransmitter release. Additionally, some antipsychotics modulate neuroplasticity markers (e.g., brain‑derived neurotrophic factor) and inflammatory pathways, though the clinical significance remains under investigation.

Pharmacokinetics

Absorption

Oral bioavailability varies widely: chlorpromazine (~70 %), haloperidol (~70 %), risperidone (~60 %), clozapine (~60 %). First‑pass hepatic metabolism is significant for many agents, resulting in variable peak plasma concentrations (C_max) and time to peak (t_max). Rapid‑acting parenteral formulations exist for haloperidol and clozapine, facilitating crisis management.

Distribution

High lipophilicity facilitates blood‑brain barrier penetration. Volume of distribution (V_d) is typically large for lipophilic agents: haloperidol (V_d ≈ 4 L/kg), clozapine (V_d ≈ 10 L/kg). Protein binding is high (>90 % for chlorpromazine, 95 % for risperidone). CNS penetration leads to significant receptor occupancy, which is a function of free drug concentration and receptor affinity.

Metabolism

Cytochrome P450 enzymes dominate antipsychotic metabolism. Haloperidol is primarily metabolized by CYP2D6; risperidone by CYP2D6 and CYP3A4; clozapine by CYP1A2 and CYP3A4; olanzapine by CYP1A2. Genetic polymorphisms in these enzymes can alter plasma levels, necessitating therapeutic drug monitoring in certain cases. Active metabolites, such as 9-hydroxyrisperidone (paliperidone), contribute to pharmacologic activity.

Excretion

Renal elimination accounts for a minority of clearance (≈10–20 %) for most agents. Elimination half‑life (t_1/2) ranges from 6 h (ziprasidone) to >30 h (clozapine) due to extensive hepatic metabolism and long V_d. Steady‑state concentrations are typically achieved after 5–7 half‑lives. Adjustments are required in hepatic impairment, with prolonged t_1/2 and increased exposure.

Dosing Considerations

Therapeutic dosing is individualized based on clinical response, tolerability, and pharmacokinetic factors. For example, haloperidol is often initiated at 0.5–1 mg/day and titrated to 2–10 mg/day. Clozapine requires a gradual titration over weeks to mitigate neutropenia risk. Rapid dose escalation can precipitate neuroleptic malignant syndrome (NMS) or severe extrapyramidal symptoms.

Therapeutic Uses / Clinical Applications

Approved Indications

• Schizophrenia (both acute and maintenance phases) – all antipsychotics.
• Bipolar disorder (mania and mixed episodes) – atypicals such as quetiapine, olanzapine, risperidone.
• Schizoaffective disorder – atypicals and some typicals.
• Other psychotic disorders – e.g., brief psychotic episodes, psychosis secondary to neurological conditions (e.g., Parkinson’s disease).
• Clozapine – treatment‑resistant schizophrenia and prevention of recurrent suicide attempts.

Off‑Label Uses

Common off‑label applications include:

• Agitation and aggression in dementia or delirium – haloperidol or atypicals.
• Obsessive‑compulsive disorder adjunctive therapy – clozapine, olanzapine.
• Attention‑deficit/hyperactivity disorder (ADHD) adjunctive therapy – risperidone, aripiprazole.
• Depressive symptoms in major depressive disorder – quetiapine as adjunct.
• Neuroleptic malignant syndrome prophylaxis – low‑dose atypicals.

Contraindications and Precautions

• Known hypersensitivity to the drug or any component.
• Severe cardiovascular disease (e.g., uncontrolled arrhythmias) – especially with agents that prolong QT interval.
• Severe hepatic insufficiency – clozapine and olanzapine may accumulate.
• Severe renal impairment – clozapine and risperidone require dose adjustment.
• Pregnancy category B–D agents (e.g., chlorpromazine, clozapine) – careful risk–benefit assessment.

Adverse Effects

Common Side Effects

• Extrapyramidal symptoms (EPS) – dystonia, akathisia, Parkinsonism, tardive dyskinesia (especially with typicals).
• Metabolic disturbances – weight gain, hyperglycemia, dyslipidemia (prominent with clozapine, olanzapine).
• Anticholinergic effects – dry mouth, blurred vision, constipation, urinary retention (more pronounced with clozapine).
• Sedation – due to H1 antagonism.
• Orthostatic hypotension – α1 blockade.
• Neuroleptic malignant syndrome (rare but life‑threatening).

Serious / Rare Adverse Reactions

• Agranulocytosis – clozapine; requires routine leukocyte monitoring.
• QT interval prolongation – ziprasidone, thioridazine; contraindicated in patients with congenital long QT or electrolyte disturbances.
• Severe weight gain and metabolic syndrome – risk of type II diabetes and cardiovascular disease.
• Neuroleptic malignant syndrome – fever, rigidity, autonomic instability; high mortality if untreated.
• Serotonin syndrome – rare, especially when combined with serotonergic agents.

Black‑Box Warnings

• Clozapine – risk of agranulocytosis, myocarditis, seizures; mandatory monitoring of absolute neutrophil count (ANC) and white blood cell count (WBC).
• Ziprasidone – QT prolongation; caution in patients with cardiac disease or electrolyte imbalance.

Drug Interactions

Major Drug‑Drug Interactions

• Cytochrome P450 inhibitors (e.g., fluoxetine, clarithromycin) increase plasma levels of agents metabolized by CYP2D6/CYP3A4, potentially augmenting EPS or sedation.
• Cytochrome P450 inducers (e.g., carbamazepine, rifampin) decrease plasma concentrations of clozapine and olanzapine, reducing efficacy.
• Serotonergic agents (e.g., SSRIs, SNRIs) may potentiate serotonin syndrome when combined with atypicals possessing significant 5‑HT2A antagonism.
• QT‑prolonging drugs (e.g., ondansetron, amiodarone) may have additive effects with ziprasidone.
• Combining anticholinergic agents (e.g., oxybutynin) with clozapine may exacerbate anticholinergic toxicity.

Contraindicated Combinations

• Clozapine with lithium – increased risk of agranulocytosis.
• Ziprasidone with potent CYP2D6 inhibitors (e.g., fluoxetine) – risk of QT prolongation.
• High‑dose clozapine with benzodiazepine sedation – may result in profound CNS depression.

Special Considerations

Pregnancy and Lactation

Most antipsychotics are classified as pregnancy category B or C, with limited data on fetal outcomes. Clozapine and chlorpromazine cross the placenta and may pose teratogenic risk; careful risk–benefit analysis is required. Breastfeeding is generally discouraged with clozapine due to potential for neonatal agranulocytosis; however, low‑dose risperidone may be acceptable under monitoring.

Pediatric Considerations

Use in children is restricted to specific indications (e.g., schizophrenia, bipolar disorder). Dosage is weight‑based and generally lower than adult equivalents. Monitoring for extrapyramidal symptoms, metabolic effects, and growth disturbances is essential. Clozapine is rarely used in pediatrics due to agranulocytosis risk.

Geriatric Considerations

Older adults exhibit increased sensitivity to antipsychotic side effects. Polypharmacy heightens interaction risk, especially with anticholinergic burden. Reduced hepatic clearance and altered pharmacokinetics necessitate dose reductions and careful titration. Monitoring for orthostatic hypotension and falls is advisable.

Renal and Hepatic Impairment

Hepatic dysfunction prolongs t_1/2 for most agents; dose adjustments are recommended. Renal impairment primarily affects agents with significant renal elimination (e.g., clozapine). Monitoring of blood levels and clinical response guides dose modifications.

Summary / Key Points

• Antipsychotics are classified into typical and atypical agents, each with distinct receptor profiles and side‑effect spectrums.
• Dopamine D₂ antagonism underlies antipsychotic efficacy, while serotonin 5‑HT₂A antagonism contributes to improved tolerability and negative symptom control.
• Pharmacokinetics vary widely; hepatic metabolism via CYP450 enzymes is a major determinant of drug exposure.
• Therapeutic uses extend beyond schizophrenia to bipolar disorder, schizoaffective disorder, and various off‑label indications.
• Adverse effects range from EPS and metabolic syndrome to agranulocytosis and QT prolongation; black‑box warnings necessitate vigilant monitoring.
• Drug interactions, particularly involving CYP450 modulators and QT‑prolonging agents, can alter efficacy and safety.
• Special populations—pregnant women, children, geriatrics, and patients with organ impairment—require individualized dosing and close surveillance.

Clinical pearls for optimizing antipsychotic therapy include initiating treatment at the lowest effective dose, employing gradual titration to mitigate adverse reactions, monitoring laboratory parameters (e.g., ANC for clozapine), and regularly reassessing risk–benefit balance, especially in vulnerable populations.

References

1. Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 5th ed. Cambridge: Cambridge University Press; 2021.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
5. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.